-
Precision-engineered profits: How to invest in genomics
Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals. Smart investors should buy in now, says Matthew Partridge
-
Should you invest in Tesla?
Tesla shares still look expensive, despite plunging 48% in recent months
-
LendInvest: a promising fintech firm going cheap
Opinion LendInvest has made some mistakes in the past, but it’s now primed for growth, says Rupert Hargreaves
Opinion -
Tesco braces for supermarket price war with rival Asda
Tesco, Britain’s biggest grocer, has opted to cut its prices more quickly to prevent Asda grabbing market share
-
Can a rebrand save WH Smith?
Opinion WH Smith's high-street shops have had their day and a change of owner is unlikely to turn things around, says Matthew Lynn
Opinion -
Nvidia shares slump as Trump tightens export controls
Confirmation that its H20 AI chips will need a license to be exported to China has hurt Nvidia’s shares, after a volatile two weeks following the announcement of sweeping tariffs on US imports
-
Anne Wojcicki: the daring 23andMe CEO who reached too far
Profile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
Profile -
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
Opinion -
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
